AzTrials
AzTrials

InfertilityFERTIMPACTNCT07562958

Fertility Impact of Microplastics - Advancing Countermeasures and Tracking

An observational study of Infertility and Microplastics Exposure, run by University of Kragujevac.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

FERTIMPACT is a prospective clinical study based on the hypothesis that exposure to micro- and nanoplastics (MNPs) is associated with impaired reproductive function. The study will quantify MNPs in human reproductive biospecimens (semen, follicular fluid, endometrial samples, stool and serum) and evaluate their… Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Infertility, Microplastics Exposure, Fertility
How many people
1,000 participants
Where
No sites listed yet
Study dates
Sep 2027to Oct 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Adult

Study population: Adults of reproductive age

Who may be able to join

  • Men: 18-55 years and women: 18-45 years (premenopausal).
  • Residence: ≥ 2 years in the participating region.
  • Ability to give informed consent and complete questionnaires (diet, lifestyle, occupational exposure).
  • Willingness to provide required samples: semen, serum, stool for men and for women serum, stool, follicular fluid and endometrial sample.
  • Availability for study visits and compliance with pre-analytical rules: Abstinence 2-7 days before semen collection and timed sampling in women (e.g., follicular phase or per protocol).
  • For patient cohort: diagnosed reproductive disorder per site SOPs (e.g., male factor infertility, endometriosis, diminished ovarian reserve).
  • For control cohort: no known infertility diagnosis; trying to conceive or healthy volunteers.
  • Necessary for all participants will be possess the ability to understand the information contained in the "informed consent" document.

Who cannot join

  • Pregnancy or lactation.
  • Acute febrile illness or active urogenital/reproductive tract infection in the last 4 weeks.
  • Systemic therapies likely to confound biomarkers within prespecified windows: chemotherapy/radiotherapy (past 12 months), high-dose corticosteroids/immunosuppressants (past 3 months), hormonal stimulation outside scheduled ART cycles per protocol.
  • Substance abuse (investigator judgment) impeding consent/compliance.

About this study

FERTIMPACT is a prospective clinical study based on the hypothesis that exposure to micro- and nanoplastics (MNPs) is associated with impaired reproductive function. The study will quantify MNPs in human reproductive biospecimens (semen, follicular fluid, endometrial samples, stool and serum) and evaluate their association with clinically relevant fertility parameters, including semen, follicular fluid, and endometrial samples quality, and assisted reproductive technology (ART) outcomes. By integrating biomonitoring with standardized clinical assessment, the study aims to provide robust evidence on exposure-effect relationships in real-world populations undergoing infertility evaluation. This will contribute to improved understanding of environmental determinants of reproductive health and support future risk assessment strategies.

Read the detailed description

Although the presence of MNPs in the human body, including reproductive fluids and placental tissue, has recently been documented, their health implications remain poorly understood, particularly in the context of the function of the human reproductive system. FERTIMPACT is the first project to systematically investigate the links between MNP exposure and reproductive toxicity by leveraging Machine Learning (ML) and multi-omics, while also exploring transgenerational effects, enabling real-time risk prediction and tracking through an integrated AI-driven platform, and developing evidence-based countermeasures and policy tools for exposure reduction. The project introduces several innovative and ground-breaking elements, derived from several diagnostic needs, including an integrated methodological approach that combines state-of-the-art label-free spectroscopic imaging techniques, thermo-analytical tools, advanced particle characterization methods and multiparametric graphene-based biosensing at the point of care for comprehensive exposure assessment in the human body and environment; a novel conceptual framework linking environmental contamination to reproductive dysfunction via shared molecular mechanisms such as oxidative stress, endocrine disruption, and genotoxicity; an AI-powered Environmental Health Intelligence Platform capable of integrating environmental and health data to dynamically assess exposure-health relationships and generate real-time risk maps; and a transdisciplinary approach bridging lab-based science with public health action through environmental monitoring, clinical research, AI, and regulatory science. Crucially, FERTIMPACT emphasizes co-development of policy recommendations and mitigation strategies with stakeholders to ensure meaningful real-world impact and uptake. Preliminary patent and publication searches indicate no prior integrated platform that combines real-world biomonitoring, mechanistic analysis, and predictive modeling of MNPs reproductive risks at this scale. Recent publication form the scientific foundation, but FERTIMPACT will extend these findings into actionable health interventions.

Link from scientific questions to answer by the FERTIMPACT clinical study: reliable detection of MNPs in human reproductive fluids. Scientific question 1#: How to develop and validate standard, contamination-controlled SOPs for semen, serum, stool, endometrial samples and follicular fluid and create interoperable protocols across EU labs? Is it possible to develop a graphene-based multiparametric biosensing platform for the rapid detection of MNPs and measure its impact on humans? FERTIMPACT answer: Reliable detection of MNPs in human reproductive fluids. Development and validation of standardized, contamination-controlled SOPs for semen, serum, stool, endometrial samples and follicular fluid. Creation of interoperable protocols across EU labs. Deployment of a graphene-based multiparametric biosensing platform for the rapid detection of MNPs and its impact on humans at the point of care. Scientific question 2#: How to harmonize of analytical methods across centres? How to make a label-free spectroscopic characterization methods and introduce it into a comprehensive, validated workflow? How to make a linking MNPs presence to clinical reproductive outcomes. FERTIMPACT answer: First prospective, human biomonitoring cohort systematically connecting MNPs burden to semen quality, ovarian reserve, and hormonal parameters. Scientific question 3#: How to elucidate mechanistic understanding of MNP-induced reproductive toxicity? FERTIMPACT answer: Application of omics to uncover molecular pathways (oxidative stress, endocrine disruption, genotoxicity) and identify biomarkers. Scientific question 4#: How to integrate a heterogeneous datasets (environmental, clinical, lab)? FERTIMPACT answer: Deployment of an AI-powered Environmental Health Intelligence Platform, enabling dynamic risk modelling, prediction, and early warning capabilities. Scientific question 5#: How to make a tool to predict and prevent MNPs related health risks? FERTIMPACT answer: Development of real-time risk maps, exceedance forecasts, anomaly detection, and citizen-facing alerts, ensuring actionable early warning for health authorities and the public. Scientific question 6#: How to translate scientific findings into policy and public health strategy? FERTIMPACT answer: Stakeholder co-creation of countermeasures, validated behavioural and regulatory interventions, and evidence-based recommendations for EU environmental and reproductive health policies.

Although the present study is non-interventional, it is based on a biologically plausible hypothesis supported by emerging experimental and translational evidence. Micro- and nanoplastics (MNPs) have been shown to induce oxidative stress, leading to the generation of reactive oxygen species and disruption of cellular homeostasis, which may impair gamete quality and reproductive function. In addition, MNPs can act as carriers of endocrine-disrupting chemicals, potentially interfering with hormonal regulation critical for reproductive processes. Experimental studies have also demonstrated genotoxic effects, including DNA damage and chromosomal instability, which may affect fertility and early embryonic development. These mechanisms provide a strong biological rationale for investigating the association between MNP exposure and reproductive outcomes in human populations. However, clinical evidence in humans remains limited, particularly in well-defined reproductive cohorts, justifying the need for the proposed prospective clinical study.

Keywords
Fertility, microplastics, IVF, micronanoplastics
Medical subject headings
Infertility

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical pregnancy rate

    Clinical pregnancy defined as the presence of a gestational sac with fetal heartbeat confirmed by transvaginal ultrasound at 6-8 weeks of gestation, according to ICMART criteria.

    Measured: 6-8 weeks after ART procedure

  2. Concentration of micro- and nanoplastics (MNPs) in reproductive biospecimens

    Quantification of concentration MNPs in semen, follicular fluid, endometrial samples, stool, and serum using validated spectroscopic and microscopic methods, expressed as particle number and size distribution per sample volume.

    Measured: At baseline (time of sample collection)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2026
  2. Study startSep 2027 (estimated)
  3. Primary completionSep 2029 (estimated)
  4. Study completionOct 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07562958
Sponsor's protocol ID
FERTIMPACT - 101289228-2
Acronym
FERTIMPACT
Status last verified
Apr 2026
First submitted
11 Apr 2026
Last updated
1 May 2026
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Infertility and Microplastics Exposure, run by University of Kragujevac.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical pregnancy rate (time frame: 6-8 weeks after ART procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in